Hepatocellular Carcinoma (HCC)

1. Clinical Overview

Summary

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, accounting for 75-85% of all primary liver cancers worldwide. [1] It represents the sixth most common cancer globally and the third leading cause of cancer-related mortality, with an estimated 906,000 new cases and 830,000 deaths annually. [2] HCC typically arises in the context of chronic liver disease, with cirrhosis present in 80-90% of cases. [1,3]

The major risk factors are chronic viral hepatitis (hepatitis B virus [HBV] and hepatitis C virus [HCV]), alcohol-related liver disease, and increasingly non-alcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH). [2,4] Unlike other aetiologies, HBV can cause HCC even without established cirrhosis due to direct viral oncogenesis. [5]

HCC can be diagnosed non-invasively in cirrhotic patients using characteristic imaging patterns on multiphasic CT or MRI, showing arterial phase hyperenhancement (APHE) with portal venous or delayed phase washout. [6,7] This negates the need for biopsy in most cases and avoids the risk of tumour seeding.

Treatment is highly dependent on tumour stage (Barcelona Clinic Liver Cancer [BCLC] staging system), underlying liver function (Child-Pugh classification), and performance status. [8] Options range from curative treatments (surgical resection, liver transplantation, thermal ablation) to locoregional therapies (transarterial chemoembolisation [TACE], transarterial radioembolisation [TARE]) and systemic therapy. The combination of atezolizumab (immune checkpoint inhibitor) plus bevacizumab (anti-VEGF antibody) is now the standard first-line systemic therapy for advanced HCC, superseding sorafenib. [9,10]

Surveillance with 6-monthly ultrasound (with or without alpha-fetoprotein [AFP]) in at-risk populations is essential for early detection and improved outcomes. [11,12]

Key Facts

• Global Burden: 6th most common cancer, 3rd leading cause of cancer death worldwide [2]
• Cirrhosis Association: 80-90% of HCC arises in cirrhotic livers [1,3]
• Major Risk Factors: HBV, HCV, alcohol, NASH/MASH, aflatoxin exposure [2,4]
• Surveillance: 6-monthly ultrasound ± AFP in all cirrhotic patients [11,12]
• Non-Invasive Diagnosis: Multiphasic CT/MRI with LI-RADS classification [6,7]
• Curative Options: Resection, liver transplantation (Milan criteria), ablation [8,13]
• Locoregional Therapy: TACE, TARE for intermediate-stage disease [14,15]
• Systemic Therapy: Atezolizumab-bevacizumab first-line for advanced HCC [9,10]
• 5-Year Survival: 70-80% post-transplant (Milan), 50-70% post-resection, less than 5% advanced disease [13,16]

Clinical Pearls

"Cirrhosis is the Biggest Risk Factor": 80-90% of HCC occurs in cirrhotic livers. Screen ALL cirrhotics with 6-monthly ultrasound. [1,11]

"No Biopsy Needed for Typical HCC": If multiphasic CT/MRI shows arterial enhancement + portal venous washout (LI-RADS 5) in a cirrhotic liver, diagnosis is confirmed without biopsy. [6,7]

"Milan Criteria for Transplant": Single tumour ≤5cm OR up to 3 tumours each ≤3cm, with no macrovascular invasion or extrahepatic spread. [13]

"HBV Can Cause HCC Without Cirrhosis": Unlike HCV or alcohol, HBV integrates into host DNA and has direct oncogenic effects. Screen high-risk HBV carriers even without cirrhosis. [5]

"AFP is Imperfect": Only 60-70% of HCCs produce elevated AFP. Normal AFP does NOT exclude HCC. [17]

"Atezolizumab-Bevacizumab is Now Standard": IMbrave150 trial demonstrated superior overall survival (19.2 vs 13.4 months) versus sorafenib for first-line advanced HCC. [9,10]

---

2. Epidemiology

Global Incidence

Hepatocellular carcinoma is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. [2] In 2020, there were an estimated 906,000 new cases and 830,000 deaths globally. The incidence-to-mortality ratio is approximately 0.91, reflecting the poor overall prognosis of this disease. [2]

Regional Variation:

• Highest incidence: East Asia (particularly China, accounting for ~50% of global cases), sub-Saharan Africa (due to endemic HBV and aflatoxin exposure) [2,18]
• Intermediate incidence: Southern Europe, Japan
• Lower incidence: North America, Northern Europe
• Rising incidence: Western countries (driven by HCV, alcohol, and NASH/MASH epidemics) [4,18]

In the United Kingdom, approximately 6,200 new cases are diagnosed annually, with age-standardised incidence rates of 10.2 per 100,000 in males and 3.0 per 100,000 in females. [18]

Demographics

Age and Sex:

• Male predominance: M:F ratio 2-3:1 globally (hormonal factors may play a role) [2]
• Peak incidence: 50-70 years in Western countries; 40-60 years in endemic HBV regions [18]
• Earlier onset: In HBV-endemic areas due to perinatal/early childhood transmission

Ethnic Variation:

• Highest rates: Asian (especially Chinese, Vietnamese, Korean) and African populations [18]
• HBV-related HCC: More common in Asian and African populations
• HCV-related HCC: More common in Egyptian, Japanese, and Southern European populations
• NASH-related HCC: Increasing in Western populations with obesity and metabolic syndrome [4]

Risk Factors and Relative Risk

Preventable Causes

Primary Prevention:

1. HBV vaccination: Universal vaccination programs have reduced HCC incidence in Taiwan, South Korea, and The Gambia [5]
2. HCV treatment: Direct-acting antivirals (DAAs) achieving sustained virologic response (SVR) reduce HCC risk by 70-80%, though not to zero [19]
3. Alcohol reduction: Abstinence or reduced consumption in at-risk individuals
4. Aflatoxin control: Food storage and contamination prevention in endemic areas
5. Weight management: Prevention and treatment of obesity and metabolic syndrome [20]

Secondary Prevention (Surveillance):

• 6-monthly ultrasound in all cirrhotic patients reduces HCC mortality by 37% [11,12]
• Earlier detection enables curative treatments

---

3. Pathophysiology

Hepatocarcinogenesis: The Multi-Step Process

Hepatocellular carcinoma develops through a multi-step process involving chronic liver injury, inflammation, fibrosis, cirrhosis, dysplasia, and ultimately malignant transformation. [21] This process typically takes 20-30 years from initial liver injury to HCC development.

Sequential Pathological Progression:

1. Chronic hepatocyte injury (viral, toxin, metabolic)
2. Inflammation and oxidative stress → DNA damage, reactive oxygen species
3. Fibrosis → collagen deposition, matrix remodelling
4. Cirrhosis → nodular regeneration, architectural disruption
5. Dysplastic nodules (low-grade → high-grade dysplasia)
6. Early HCC → advanced HCC

The cirrhotic liver is characterized by continuous cycles of necrosis, inflammation, and regeneration, creating a microenvironment conducive to genetic and epigenetic alterations. [21]

Molecular Pathways in HCC

HCC is a molecularly heterogeneous disease with multiple driver pathways: [21,22]

Major Oncogenic Pathways:

1. WNT/β-Catenin Pathway Activation (30-40% of HCCs)

   • CTNNB1 mutations (exon 3) prevent β-catenin degradation
   • Nuclear accumulation of β-catenin → transcriptional activation
   • Associated with well-differentiated tumours, better prognosis
   • More common in HCV and alcohol-related HCC [22]

2. TP53 Inactivation (30-40% of HCCs)

   • Mutations (especially R249S from aflatoxin exposure)
   • Loss of cell cycle checkpoint and apoptosis control
   • Associated with poorly differentiated tumours, poor prognosis [22]

3. Telomerase Reactivation (60-90% of HCCs)

   • TERT promoter mutations (most common genetic alteration)
   • Enable replicative immortality
   • Early event in hepatocarcinogenesis [22]

4. RAS/MAPK/ERK Pathway Dysregulation

   • Receptor tyrosine kinase (RTK) overexpression/activation
   • Promotes cell proliferation and survival
   • Target for multi-kinase inhibitors (sorafenib, lenvatinib) [22]

5. PI3K/AKT/mTOR Pathway Activation

   • PIK3CA mutations, PTEN loss
   • Promotes growth, metabolism, survival [22]

6. Oxidative Stress and Inflammation

   • NRF2 pathway activation
   • NFκB pathway activation → pro-inflammatory cytokines [21]

Tumour Suppressor Inactivation:

• CDKN2A (p16) loss
• RB1 inactivation
• AXIN1 mutations
• ARID1A/ARID2 chromatin remodelling gene mutations [22]

Aetiology-Specific Mechanisms

Hepatitis B Virus (HBV):

• HBV DNA integrates randomly into host genome → insertional mutagenesis [5]
• HBx protein has direct oncogenic effects:
  • Transactivates cellular genes
  • Inhibits p53 function
  • Activates RAS/MAPK and PI3K/AKT pathways [5]
• Can cause HCC without cirrhosis (unique among aetiologies)
• Chronic inflammation and oxidative stress

Hepatitis C Virus (HCV):

• Does NOT integrate into host genome
• HCC occurs almost exclusively with cirrhosis [19]
• Mechanisms:
  • Chronic inflammation → oxidative stress → DNA damage
  • Core protein alters cell signalling
  • Immune-mediated hepatocyte injury
• SVR reduces but does not eliminate HCC risk [19]

Alcohol:

• Acetaldehyde is directly genotoxic
• Oxidative stress and reactive oxygen species (ROS)
• Inflammation and immune dysregulation
• Epigenetic modifications (DNA methylation changes)
• Synergistic with viral hepatitis [18]

NASH/MASH:

• Lipotoxicity → hepatocyte injury and apoptosis
• Oxidative stress from lipid peroxidation
• Inflammatory cytokines (TNF-α, IL-6)
• Insulin resistance and hyperinsulinaemia → IGF-1 pathway activation
• Can occur without cirrhosis (20-30% of NASH-HCC) [4,20]
• Gut microbiome dysbiosis may contribute

Aflatoxin B1:

• Metabolized to aflatoxin-8,9-epoxide (highly mutagenic)
• Causes specific TP53 mutation (AGG→AGT, R249S codon)
• Synergistic with HBV (> 60-fold increased risk) [18]

Tumour Biology and Growth Patterns

Vascular Supply:

• HCC is hypervascular with predominantly arterial blood supply (vs. normal liver 75% portal venous)
• Arterialisation occurs early in dysplastic nodules
• Basis for imaging diagnosis (arterial enhancement) [6,7]

Growth Patterns:

• Expansive (pushing margins)
• Infiltrative (invading margins, worse prognosis)
• Multifocal (intrahepatic metastases vs. multifocal primaries)

Portal Vein Invasion:

• Occurs in 10-40% of HCCs at diagnosis
• Major adverse prognostic factor
• Can cause Budd-Chiari-like syndrome if extends to hepatic veins/IVC [23]

Tumour Markers:

• Alpha-fetoprotein (AFP): Produced by 60-70% of HCCs
• Des-gamma-carboxy prothrombin (DCP/PIVKA-II): Alternative marker
• AFP-L3 (fucosylated AFP isoform): More specific for HCC [17]

---

4. Clinical Presentation

Symptoms

HCC is often asymptomatic in early stages, especially when detected through surveillance programs. Symptomatic presentation typically indicates advanced disease. [1,8]

Common Presenting Symptoms:

Symptoms of Hepatic Decompensation:

• Jaundice (10-30%): New or worsening in known cirrhotic; suggests advanced disease or biliary obstruction
• Ascites (20-40%): New or worsening; may be due to HCC or progression of cirrhosis
• Hepatic encephalopathy (10-20%): Confusion, altered consciousness
• Variceal bleeding (5-10%): Due to portal hypertension

Acute Presentations (RED FLAGS):

• Tumour rupture (3-15% lifetime risk): Sudden severe abdominal pain, peritonitis, haemorrhagic shock [23]
  • Medical emergency; mortality 25-75% depending on management
  • More common in subcapsular tumours > 5cm
• Acute portal vein thrombosis: Sudden onset ascites, abdominal pain
• Budd-Chiari syndrome: Hepatic vein/IVC invasion → hepatomegaly, ascites, acute liver failure

Signs

Examination Findings:

General:

• Cachexia (muscle wasting, temporal wasting)
• Jaundice
• Lymphadenopathy (Virchow's node in metastatic disease)

Abdominal:

• Hepatomegaly (50-80%): May be smooth or nodular; palpable mass in advanced disease
• Hepatic bruit (uncommon, less than 10%): Arterial flow in hypervascular tumour
• Ascites (20-40%): Assess for shifting dullness, fluid thrill
• Splenomegaly (30-50%): Portal hypertension
• Caput medusae: Visible periumbilical venous collaterals

Stigmata of Chronic Liver Disease:

• Spider naevi (upper body distribution)
• Palmar erythema
• Leukonychia (white nails)
• Clubbing (rare)
• Dupuytren's contracture (alcohol-related)
• Gynecomastia (in males)
• Testicular atrophy
• Loss of axillary/pubic hair

Asterixis ("Liver Flap"):

• Sign of hepatic encephalopathy
• Ask patient to extend arms and dorsiflex wrists
• Characteristic flapping tremor

Paraneoplastic Syndromes

Occur in 10-20% of HCCs: [23]

---

5. Clinical Examination

Structured Approach

Performance Status Assessment:

• ECOG Performance Status (0-4):
  • 0: Fully active, no restrictions
  • 1: Restricted in strenuous activity; ambulatory, able to carry out light work
  • 2: Ambulatory, capable of self-care; unable to work; up > 50% of waking hours
  • 3: Limited self-care; confined to bed/chair > 50% of waking hours
  • 4: Completely disabled; totally confined to bed/chair
• Essential for BCLC staging and treatment decisions [8]

Liver Function Assessment: Child-Pugh Score

Critical for surgical candidacy and treatment allocation. [8]

Classification:

• Child-Pugh A (5-6 points): Good hepatic reserve; eligible for resection, transplant, ablation
• Child-Pugh B (7-9 points): Moderate impairment; consider transplant, TACE; resection high risk
• Child-Pugh C (10-15 points): Severe impairment; best supportive care; transplant only option if tumour criteria met

Alternative: MELD Score (Model for End-Stage Liver Disease)

Used primarily for transplant prioritization:

MELD = 3.78×ln[bilirubin(mg/dL)] + 11.2×ln[INR] + 9.57×ln[creatinine(mg/dL)] + 6.43

• Score 6-40; higher = worse prognosis
• Used with MELD-Na (includes serum sodium)

Abdominal Examination Sequence

1. Inspection: Distension, visible masses, caput medusae, surgical scars
2. Palpation: Hepatomegaly (size, consistency, nodularity, tenderness), splenomegaly, masses
3. Percussion: Liver span, ascites (shifting dullness)
4. Auscultation: Bowel sounds, hepatic bruit (rare)

Encephalopathy Grading (West Haven Criteria)

---

6. Investigations

Surveillance in At-Risk Populations

Who to Surveil:

• All patients with cirrhosis (any aetiology) [11,12]
• Non-cirrhotic HBV carriers: Asian males > 40 years, African > 20 years, family history of HCC, HBV DNA > 2000 IU/mL [5,11]
• Non-cirrhotic HCV with advanced fibrosis (F3) [11]

Surveillance Protocol:

• 6-monthly abdominal ultrasound (sensitivity 60-80% for early HCC) [11,12]
• ± Serum AFP (controversial; increases sensitivity by 5-10% but reduces specificity) [11,12,17]
• GALAD score (Gender, Age, AFP-L3, AFP, DCP) may improve detection rates [17]

Surveillance Benefits:

• 37% reduction in HCC mortality [12]
• Increased detection of early-stage HCC amenable to curative treatment
• Cost-effective in cirrhotic populations

Diagnostic Imaging

Multiphasic CT or MRI with Contrast:

Gold standard for HCC diagnosis in cirrhotic livers. [6,7]

Phases:

1. Non-contrast (baseline attenuation)
2. Arterial phase (25-30 seconds post-contrast): HCC shows hyperenhancement (APHE)
3. Portal venous phase (60-70 seconds): Washout appearance (hypointense relative to liver)
4. Delayed phase (3-5 minutes): Further washout, capsule appearance

LI-RADS (Liver Imaging Reporting and Data System) v2018: [7]

Standardized reporting system for observations in at-risk patients.

LI-RADS 5 Criteria (Diagnostic of HCC):

• ≥10mm with APHE and ≥1 of:
  • "Washout" on portal venous or delayed phase
  • Enhancing "capsule"
  • Threshold growth (≥50% diameter increase in ≤6 months)

Contrast-Enhanced Ultrasound (CEUS):

• Second-line modality
• Uses microbubble contrast agents (SonoVue)
• Can characterize lesions in real-time
• Limited by operator dependence and body habitus [6]

MRI with Hepatobiliary Contrast (Primovist/Eovist):

• Gadoxetate disodium is taken up by functioning hepatocytes
• HCC lacks normal hepatocyte uptake → hypointense on hepatobiliary phase (20 min)
• Higher sensitivity than CT for small lesions [6,7]

Tumour Markers

Alpha-Fetoprotein (AFP): [17]

• Glycoprotein normally produced by fetal liver, yolk sac
• Elevated in 60-70% of HCCs
• Interpretation:
  • less than 20 ng/mL: Normal (does NOT exclude HCC)
  • 20-400 ng/mL: Non-specific; can be elevated in cirrhosis, chronic hepatitis, pregnancy, germ cell tumours

  • 400 ng/mL: Highly suggestive of HCC (specificity > 90%)

  • 1000 ng/mL: Associated with advanced disease, macrovascular invasion, worse prognosis

• Limitations:
  • 30-40% of HCCs are AFP-negative
  • Elevated in non-malignant conditions (cirrhosis flares)
  • Not recommended as standalone surveillance tool by EASL [11]

Additional Markers:

• AFP-L3 (fucosylated AFP isoform): > 10% total AFP more specific for HCC [17]
• DCP (Des-gamma-carboxy prothrombin, PIVKA-II): Independent marker; > 40 mAU/mL suggestive [17]
• GALAD Score: Combines Gender, Age, AFP-L3, AFP, DCP; AUROC 0.87-0.97 for HCC detection [17]

Biopsy

When to Biopsy:

• NOT required if classic imaging features (LI-RADS 5) in cirrhotic liver [6,11]
• Consider if:
  • Atypical imaging features (LR-3, LR-4, LR-M)
  • Non-cirrhotic liver
  • Diagnostic uncertainty (? cholangiocarcinoma, metastasis)
  • Clinical trial enrollment requiring histology

Biopsy Risks:

• Needle tract seeding: 1-3% risk; contraindication in transplant candidates [6]
• Bleeding
• Pneumothorax (if transthoracic approach)

Histopathology:

• Well, moderately, or poorly differentiated HCC
• Immunohistochemistry: Arginase-1, Glypican-3, HepPar-1 (HCC markers)
• Cytokeratin 7/19 (usually negative; positive in cholangiocarcinoma)

Staging Investigations

After HCC Diagnosis:

1. Triphasic CT chest/abdomen/pelvis:

   • Assess extrahepatic disease (lungs, lymph nodes, adrenals, bones, peritoneum)
   • Portal vein patency
   • Arterial anatomy (for TACE/TARE planning or resection)

2. MRI liver (if not already done):

   • More sensitive for satellite lesions
   • Hepatobiliary phase for additional nodules

3. Bone scan (if symptomatic): Skeletal metastases

4. Brain MRI (if symptomatic or before transplant workup)

5. Laboratory tests:

   • Full blood count, renal function, liver function tests
   • Coagulation (INR, PT)
   • Viral serology (HBV DNA, HCV RNA, HIV)
   • AFP

Assess Fitness for Surgery:

• Echocardiography
• Pulmonary function tests (if lung disease)
• Cardiopulmonary exercise testing (CPET) for major resection

---

7. Management

Staging: Barcelona Clinic Liver Cancer (BCLC) System

Most widely used prognostic and treatment allocation system. [8]

BCLC Limitations:

• Does not account for molecular heterogeneity
• Dichotomizes continuous variables
• May understage patients with portal vein thrombosis who can benefit from aggressive therapy

Curative Treatments

1. Surgical Resection

Indications:

• Non-cirrhotic liver: Resectable tumour with adequate future liver remnant (FLR ≥20%)
• Cirrhotic liver: Child-Pugh A, no portal hypertension, single tumour, adequate FLR (≥40%)
• ECOG 0-1 [16]

Contraindications:

• Child-Pugh B/C (high risk of post-hepatectomy liver failure)
• Portal hypertension (platelet less than 100×10⁹/L, varices, splenomegaly)
• Extrahepatic metastases
• Macrovascular invasion (relative; some centres offer resection)

Outcomes:

• 5-year overall survival: 50-70% [16]
• Recurrence rate: 70% at 5 years (50% early recurrence less than 2 years = metastatic; 50% late = new primary)
• Perioperative mortality: 2-5% in Child-Pugh A; > 10% in Child-Pugh B

Extent of Resection:

• Anatomical (segmental/sectoral) preferred over non-anatomical
• Parenchymal-sparing surgery in cirrhosis to preserve liver function
• Major resection (≥3 segments) vs. minor resection

Post-Resection Surveillance:

• CT/MRI every 3-4 months for 2 years, then 6-monthly
• AFP monitoring

2. Liver Transplantation

Advantages:

• Removes tumour AND treats underlying cirrhosis
• Lowest recurrence rate of any treatment
• Best long-term survival for selected patients [13]

Milan Criteria (Standard Criteria): [13]

• Single tumour ≤5cm OR
• Up to 3 nodules, each ≤3cm
• No macrovascular invasion
• No extrahepatic spread

Outcomes within Milan Criteria:

• 5-year survival: 70-80% [13]
• Recurrence rate: 10-15% at 5 years

Expanded Criteria:

• UCSF (University of California San Francisco):
  • Single ≤6.5cm OR
  • ≤3 nodules ≤4.5cm with total diameter ≤8cm
• Up-to-Seven Criteria:
  • Sum of number of tumours and size of largest tumour (cm) ≤7
• Outcomes with expanded criteria: 5-year survival 60-70% [13]

Downstaging:

• Locoregional therapies (TACE, TARE, ablation) to reduce tumour burden to within Milan
• If stable for 3-6 months, may list for transplant
• Intention-to-treat survival similar to primary Milan [13]

Allocation:

• MELD exception points to reflect dropout risk
• Regional variation in organ availability affects wait times

Contraindications:

• Extrahepatic metastases
• Macrovascular invasion
• Performance status ECOG > 2
• Active alcohol/substance use
• Medical comorbidities precluding surgery

3. Percutaneous Ablation (RFA/MWA)

Indications:

• BCLC 0 or A: Single tumour ≤3cm or ≤3 nodules each ≤3cm
• Child-Pugh A-B
• Not suitable for resection or as bridge to transplant [14]

Modalities:

• Radiofrequency ablation (RFA): Thermal injury via alternating current; effective for tumours ≤3cm
• Microwave ablation (MWA): Higher temperatures, less heat-sink effect; better for tumours 3-5cm
• Irreversible electroporation (IRE): Non-thermal; for tumours near bile ducts/vessels

Technique:

• Percutaneous (ultrasound or CT-guided)
• Laparoscopic (for difficult locations)

Outcomes:

• Complete ablation: > 90% for tumours less than 3cm [14]
• 5-year survival: 50-70% (comparable to resection for small tumours) [14]
• Recurrence: 60-70% at 5 years (local recurrence 5-15%)

Complications:

• Post-ablation syndrome (fever, pain): 30-50% (self-limiting) [14]
• Bleeding: 1-2%
• Liver abscess: less than 1%
• Biliary injury: Rare
• Tumour seeding: less than 1%

Contraindications:

• Tumours > 5cm (incomplete ablation)
• Subcapsular location (rupture risk)
• Proximity to major bile ducts (> 5mm → stricture risk)
• Coagulopathy (INR > 1.5, platelets less than 50×10⁹/L)

Locoregional Therapies

4. Transarterial Chemoembolisation (TACE)

Indication:

• BCLC B (intermediate stage): Multinodular HCC, no vascular invasion, no extrahepatic spread
• Child-Pugh A-B, ECOG 0 [14,15]

Mechanism:

• Delivers chemotherapy (doxorubicin, cisplatin, mitomycin) directly to tumour via hepatic artery
• Embolization with lipiodol or drug-eluting beads (DEB-TACE) → tumour ischemia

Procedure:

• Selective catheterization of tumour-feeding arteries
• Injection of chemotherapy ± embolizing agent
• Repeat sessions every 4-8 weeks until complete response or treatment failure

Outcomes:

• Median overall survival: 26-40 months (vs. 16 months untreated) [14,15]
• Objective response rate: 35-55%
• Complete response: 10-20%

Predictors of Good Response:

• Child-Pugh A
• ECOG 0
• Tumour size less than 5cm
• Absence of vascular invasion

TACE + Sorafenib:

• TACTICS trial (Japan): TACE + sorafenib improved progression-free survival vs. TACE alone [15]
• Not standard practice globally; consider in selected patients

Contraindications (Absolute):

• Child-Pugh C
• Portal vein occlusion (main trunk)
• Active infection/sepsis
• Severe renal impairment (contrast allergy/risk)
• Biliary obstruction

Contraindications (Relative):

• Tumour > 50% liver volume
• Bilirubin > 3mg/dL
• Extensive extrahepatic disease

Complications:

• Post-embolisation syndrome (80-100%): Fever, pain, nausea, vomiting; self-limiting 3-5 days [14]
• Liver failure: 3-5%; higher in Child-Pugh B
• Biloma/abscess: 1-2%
• Acute cholecystitis: 1-2%
• Tumour lysis syndrome: Rare
• Non-target embolisation: GI ulceration, cholecystitis

5. Transarterial Radioembolisation (TARE, Y-90)

Indication:

• Alternative to TACE for intermediate-stage HCC
• May have role in advanced HCC with portal vein thrombosis [14]

Mechanism:

• Yttrium-90 (Y-90) radioactive microspheres delivered via hepatic artery
• Beta-radiation (mean penetration 2.5mm) → localized tumour kill
• Less ischemia than TACE

Outcomes:

• Non-inferiority to TACE in randomized trials [14]
• Median survival 15-18 months in intermediate stage
• May downstage to transplant or ablation

Advantages over TACE:

• Single session (vs. multiple TACE)
• Less post-embolisation syndrome
• Can treat portal vein thrombosis

Contraindications:

• 30Gy lung shunt dose (pulmonary toxicity)

• 50Gy gastrointestinal dose (GI ulceration)

Systemic Therapy

First-Line: Atezolizumab + Bevacizumab

Indication:

• BCLC C (advanced HCC): Macrovascular invasion or extrahepatic spread
• Child-Pugh A, ECOG 0-1 [9,10]

IMbrave150 Trial (Landmark Study): [9,10]

• Phase 3 RCT: Atezolizumab (anti-PD-L1) + bevacizumab (anti-VEGF) vs. sorafenib
• Results:
  • "Median OS: 19.2 months vs. 13.4 months (HR 0.66, pless than 0.001)"
  • "Median PFS: 6.9 months vs. 4.3 months"
  • "Objective response rate: 30% vs. 11%"
• Updated 3-year OS: 30% vs. 20%
• Conclusion: New standard of care for first-line advanced HCC [10]

Dosing:

• Atezolizumab 1200mg IV + bevacizumab 15mg/kg IV every 3 weeks

Eligibility:

• Must have endoscopy to exclude/treat high-risk varices (bevacizumab bleeding risk)
• Adequate hepatic function (Child-Pugh A)
• No contraindications to immunotherapy or anti-VEGF therapy

Adverse Events:

• Hypertension (30%): Monitor BP, treat with antihypertensives
• Proteinuria (20%): Monitor urine protein; discontinue if nephrotic syndrome
• Bleeding (10%): GI bleeding, epistaxis
• Immune-related AEs (20-30%): Hepatitis, colitis, pneumonitis, thyroiditis, rash

Contraindications:

• Child-Pugh B/C
• Untreated/uncontrolled varices
• Active bleeding
• Autoimmune disease (relative)
• Solid organ transplant (immunosuppression contraindication)

Alternative First-Line Options

Sorafenib:

• Multi-kinase inhibitor (VEGFR, PDGFR, RAF)
• SHARP trial: OS 10.7 vs. 7.9 months (placebo) [HR 0.69] [15]
• Dosing: 400mg PO twice daily
• AEs: Hand-foot syndrome, diarrhoea, fatigue, hypertension
• Reserved for patients ineligible for atezolizumab-bevacizumab

Lenvatinib:

• Multi-kinase inhibitor (VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET)
• REFLECT trial: Non-inferior OS to sorafenib (13.6 vs. 12.3 months) [15]
• Dosing: Weight-based (12mg if ≥60kg, 8mg if less than 60kg) PO daily
• AEs: Hypertension, proteinuria, fatigue, decreased appetite
• Contraindicated in main portal vein/IVC invasion

Second-Line Systemic Therapy

After Sorafenib Failure:

• Regorafenib: OS 10.6 vs. 7.8 months (placebo) (RESORCE trial) [HR 0.63]
• Cabozantinib: OS 10.2 vs. 8.0 months (placebo) (CELESTIAL trial) [HR 0.76]
• Ramucirumab: (if AFP ≥400 ng/mL) OS 8.5 vs. 7.3 months (REACH-2 trial)

After Atezolizumab-Bevacizumab:

• Optimal sequencing unclear; sorafenib or lenvatinib reasonable options

Best Supportive Care

BCLC D (Terminal Stage):

• Child-Pugh C or ECOG 3-4
• Median survival less than 3 months [8]

Components:

• Symptom control (pain, nausea)
• Management of ascites (diuretics, paracentesis)
• Treatment of hepatic encephalopathy (lactulose, rifaximin)
• Nutritional support
• Psychosocial support
• Advanced care planning, palliative care referral

---

8. Complications

Complications of HCC

Portal Vein Thrombosis (PVT):

• Occurs in 10-40% of HCC patients [23]
• Tumour thrombus vs. bland thrombus (imaging can differentiate)
• Results in portal hypertension, ascites, variceal bleeding
• Major adverse prognostic factor (median survival 2.7-4 months untreated)
• Treatment: Consider TARE, systemic therapy, anticoagulation (if bland component)

Hepatic Decompensation:

• New or worsening ascites, jaundice, encephalopathy
• Due to tumour burden, loss of functional liver parenchyma, portal hypertension
• May necessitate transition to best supportive care

Tumour Rupture and Haemoperitoneum:

• Occurs in 3-15% lifetime risk; higher in large (> 5cm) subcapsular tumours [23]
• Presents as acute severe abdominal pain, peritonitis, haemorrhagic shock
• Emergency Management:
  1. Resuscitation (IV fluids, blood products)
  2. Imaging (CT to confirm)
  3. Urgent treatment: Transarterial embolization (TAE) OR emergency surgery
• Mortality 25-75% depending on haemodynamic stability and treatment
• If patient survives, consider staged resection or TACE

Metastatic Disease:

• Most common sites: Lungs (40%), lymph nodes (30%), bone (20%), adrenals, brain
• Worsens prognosis; systemic therapy indicated

Paraneoplastic Syndromes:

• Hypoglycaemia, hypercalcaemia, erythrocytosis, thrombocytosis (see Section 4)

Budd-Chiari Syndrome:

• HCC extension into hepatic veins/IVC
• Acute liver failure, massive ascites, hepatomegaly
• Poor prognosis

Complications of Treatment

Surgical Resection:

• Post-hepatectomy liver failure (PHLF): 2-10%; "50-50 criteria" (bilirubin > 50 μmol/L and INR > 1.5 on POD5 predicts mortality)
• Bleeding: 2-5%
• Bile leak: 3-10%
• Intra-abdominal infection/abscess: 5-10%
• Pleural effusion: 20-30%
• Mortality: 2-5% in experienced centres

Liver Transplantation:

• Surgical complications: Bleeding, vascular thrombosis (hepatic artery, portal vein), biliary complications
• Rejection (acute or chronic)
• Infection (bacterial, viral, fungal) due to immunosuppression
• Recurrent HCC: 10-15% at 5 years
• Immunosuppression-related: Renal impairment (calcineurin inhibitors), malignancy, cardiovascular disease
• Graft failure requiring retransplantation: 5-10%

Ablation (RFA/MWA):

• Post-ablation syndrome: 30-50% (fever, pain; self-limiting) [14]
• Haemorrhage: 1-2%
• Liver abscess: less than 1%
• Bile duct injury/stricture: Rare (if too close to ducts)
• Tumour seeding: less than 1%
• Pneumothorax: If transthoracic approach

TACE:

• Post-embolisation syndrome: 80-100% (see Section 7)
• Acute liver failure: 3-5% (especially Child-Pugh B/C)
• Biloma/abscess: 1-2%
• Acute cholecystitis: 1-2%
• GI ulceration (duodenal, gastric): less than 1%
• Cholangitis, sepsis

TARE (Y-90):

• Radiation pneumonitis (if > 30Gy lung dose): less than 1%
• GI ulceration (if > 50Gy GI dose): less than 1%
• Radioembolisation-induced liver disease (REILD): less than 1%
• Fatigue, nausea: 30-50%

Systemic Therapy (Atezolizumab-Bevacizumab):

• Hypertension: 30%; manage with antihypertensives
• Proteinuria: 20%; monitor urine protein
• Bleeding (GI, variceal): 10%; screen/treat varices before starting
• Immune-related AEs:
  • "Hepatitis (5-10%): May require steroids"
  • "Colitis (2-5%): Diarrhoea, abdominal pain"
  • "Pneumonitis (1-2%): Dyspnoea, cough"
  • "Endocrinopathies (5-10%): Hypothyroidism, adrenal insufficiency, diabetes"
  • "Dermatologic: Rash, pruritus (20-30%)"
• Infusion reactions: 10-20%

Systemic Therapy (Sorafenib/Lenvatinib):

• Hand-foot skin reaction (HFSR): 20-50%
• Diarrhoea: 40-60%
• Hypertension: 20-30%
• Fatigue: 30-50%
• Decreased appetite, weight loss: 20-40%
• Hepatotoxicity: Monitor LFTs

---

9. Prognosis & Outcomes

Survival by BCLC Stage

Treatment-Specific Outcomes

Prognostic Factors

Favourable Prognostic Factors:

• Early stage (BCLC 0, A)
• Single tumour, small size (less than 3cm)
• Well-differentiated histology
• Child-Pugh A liver function
• ECOG 0 performance status
• No macrovascular invasion
• No extrahepatic spread
• AFP less than 400 ng/mL
• Complete response to treatment

Adverse Prognostic Factors:

• Advanced stage (BCLC C, D)
• Multifocal disease, large tumour (> 5cm)
• Poorly differentiated histology
• Portal vein thrombosis (median survival 2.7-4 months untreated) [23]
• Extrahepatic metastases
• Child-Pugh B/C
• ECOG 2-4
• AFP > 1000 ng/mL (associated with vascular invasion, poor prognosis)
• Elevated bilirubin, low albumin, prolonged INR

Recurrence After Curative Treatment

Post-Resection Recurrence:

• Overall: 70% at 5 years [16]
• Early recurrence (less than 2 years): 50%; due to micrometastases present at surgery; worse prognosis
• Late recurrence (> 2 years): 50%; de novo HCC due to underlying cirrhosis; better prognosis

Risk Factors for Recurrence:

• Microvascular invasion (most important histological factor)
• Multifocal disease
• Tumour size > 5cm
• Poorly differentiated histology
• Satellite lesions
• Positive or narrow resection margin (less than 1cm)
• Elevated AFP

Post-Transplant Recurrence:

• Within Milan: 10-15% at 5 years [13]
• Outside Milan (expanded criteria): 20-30% at 5 years
• Recurrence typically extrahepatic (lungs, bones)
• Poor prognosis once recurrence occurs (median survival 6-12 months)

Post-Ablation Recurrence:

• Local recurrence: 5-15% at 5 years (incomplete ablation) [14]
• Distant intrahepatic recurrence: 50-60% at 5 years (new HCC)
• Salvage treatment with repeat ablation, TACE, or resection

Special Populations

NASH-Related HCC:

• Often presents at more advanced stage (less surveillance in non-cirrhotic patients) [4,20]
• 20-30% occur without cirrhosis [20]
• Older, more comorbidities (diabetes, cardiovascular disease)
• May have better liver function but worse surgical candidacy due to comorbidities

HBV-Related HCC:

• Can occur without cirrhosis (15-20% of HBV-HCC) [5]
• Younger age at presentation in endemic areas
• Antiviral therapy (tenofovir, entecavir) reduces HCC risk by 50-70% but does not eliminate it

HCV-Related HCC:

• Almost always in cirrhotic liver [19]
• SVR (sustained virologic response) reduces HCC risk by 70-80%, but not to zero [19]
• Surveillance still required post-SVR if cirrhosis present

---

10. Evidence & Guidelines

Key Clinical Practice Guidelines

1. European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma (2018) [1]

   • Comprehensive guideline covering surveillance, diagnosis, staging, and treatment
   • Recommends 6-monthly ultrasound surveillance in cirrhotic patients
   • Non-invasive diagnosis with multiphasic CT/MRI in cirrhotic liver
   • BCLC staging system for treatment allocation

2. American Association for the Study of Liver Diseases (AASLD) Practice Guidance: Diagnosis, Staging, and Management of HCC (2018) [11]

   • Aligns closely with EASL guidelines
   • Recommends surveillance in cirrhotic patients and high-risk non-cirrhotic HBV carriers
   • LI-RADS v2018 for standardized imaging interpretation

3. European Society for Medical Oncology (ESMO) Clinical Practice Guidelines: HCC (2021)

   • Systemic therapy recommendations
   • Atezolizumab-bevacizumab as first-line standard (post-IMbrave150)

4. National Institute for Health and Care Excellence (NICE) NG85: Cirrhosis in Over 16s (2016)

   • Recommends 6-monthly ultrasound surveillance in cirrhotic patients (UK-specific)

5. Asian Pacific Association for the Study of the Liver (APASL) Consensus Guidelines (2017)

   • Region-specific recommendations for high HBV prevalence areas

Landmark Clinical Trials

Surveillance:

• Meta-analysis of HCC Surveillance (Singal et al., 2022) [12]
  • Surveillance reduces HCC mortality by 37% (OR 0.63, 95% CI 0.49-0.80)
  • Increases detection of early-stage HCC (odds ratio 2.12)
  • Cost-effective in cirrhotic populations

Diagnosis:

• LI-RADS Validation Studies (Chernyak et al., 2018) [7]
  • LR-5 has 95% specificity and 70-80% sensitivity for HCC ≥10mm
  • Standardizes reporting and reduces inter-observer variability

Transplantation:

• Mazzaferro et al., Milan Criteria (NEJM 1996) [13]
  • Landmark study defining transplant eligibility criteria
  • Single ≤5cm OR ≤3 nodules ≤3cm
  • 4-year survival 75% vs. 50% for patients exceeding criteria
  • Revolutionized transplantation for HCC

Systemic Therapy:

• IMbrave150 Trial (Finn et al., NEJM 2020; updated Cheng et al., J Hepatol 2022) [9,10]

  • "Phase 3 RCT: Atezolizumab + bevacizumab vs. sorafenib in unresectable HCC"
  • "Primary endpoints: Overall survival (OS), progression-free survival (PFS)"
  • "Results: OS 19.2 vs. 13.4 months (HR 0.66, pless than 0.001); PFS 6.9 vs. 4.3 months"
  • "Updated 3-year OS: 30% vs. 20%"
  • Established new standard of care for first-line advanced HCC

• SHARP Trial (Llovet et al., NEJM 2008) [15]

  • Sorafenib vs. placebo in advanced HCC
  • OS 10.7 vs. 7.9 months (HR 0.69, pless than 0.001)
  • First systemic therapy to demonstrate OS benefit in HCC

• REFLECT Trial (Kudo et al., Lancet 2018) [15]

  • Lenvatinib non-inferior to sorafenib (OS 13.6 vs. 12.3 months)
  • Alternative first-line option

Locoregional Therapy:

• Llovet et al., J Natl Cancer Inst 2002 [14]

  • RCT of TACE vs. best supportive care
  • Improved survival with TACE (median 28 vs. 11 months)
  • Established TACE as standard for intermediate-stage HCC

• TACTICS Trial (Kudo et al., Gut 2020) [15]

  • TACE + sorafenib vs. TACE alone (Japan)
  • Improved PFS (25.2 vs. 13.5 months) with combination
  • Not universally adopted; consider in selected patients

Ablation:

• Meta-analysis of RFA vs. Resection (Uhlig et al., 2019) [14]
  • No significant difference in OS for tumours ≤3cm
  • RFA associated with less morbidity, shorter hospital stay

Recent Advances and Emerging Evidence

Novel Biomarkers:

• GALAD Score (Johnson et al., Gastroenterology 2025) [17]
  • Combines Gender, Age, AFP-L3, AFP, DCP
  • AUROC 0.87-0.97 for HCC detection; outperforms AFP alone
  • May improve surveillance sensitivity

Precision Medicine:

• Molecular subtyping of HCC (proliferative vs. non-proliferative classes) [22]
• Potential for biomarker-driven therapy selection
• Ongoing trials of molecularly targeted agents

Immunotherapy Combinations:

• Ongoing trials of dual checkpoint inhibition (anti-PD-1 + anti-CTLA-4)
• Combinations with locoregional therapy (TACE + immunotherapy)

---

11. Patient/Layperson Explanation

What is Hepatocellular Carcinoma?

Hepatocellular carcinoma (HCC), also called liver cancer, is the most common type of cancer that starts in the liver. Most liver cancers in adults are HCC, which means the cancer begins in the main liver cells (hepatocytes).

HCC usually develops in people who already have long-term liver disease, particularly cirrhosis (scarring of the liver). The liver tries to repair itself repeatedly over many years, and sometimes this process goes wrong, leading to cancer cells developing.

What Causes It?

The most common causes of HCC are conditions that damage the liver over a long period:

Viral Hepatitis:

• Hepatitis B: A virus that can be passed from mother to baby at birth, through blood, or sexual contact. It causes long-term liver inflammation.
• Hepatitis C: Spread through blood contact (e.g., sharing needles, contaminated medical equipment). Modern treatments can cure hepatitis C.

Alcohol:

• Heavy, long-term alcohol use damages the liver and causes scarring (cirrhosis), which increases cancer risk.

Fatty Liver Disease (NASH/MASH):

• Fat builds up in the liver, often linked to obesity, diabetes, and high cholesterol. Over time, this can lead to inflammation, scarring, and cancer.

Other Causes:

• Haemochromatosis (too much iron in the body)
• Certain inherited liver diseases
• Aflatoxin (a toxin from mouldy grains/nuts in some countries)

What Are the Symptoms?

In early stages, HCC often has no symptoms. This is why screening is so important for people at risk. As the cancer grows, symptoms may include:

• Pain or discomfort in the upper right side of the abdomen
• Unexplained weight loss
• Loss of appetite
• Feeling very tired or weak
• Yellowing of the skin or eyes (jaundice)
• Swelling of the abdomen (fluid buildup called ascites)
• Feeling full after eating only a small amount

Warning Signs (Seek Urgent Medical Attention):

• Sudden severe abdominal pain (may indicate tumour rupture)
• Vomiting blood or black stools
• Confusion or drowsiness
• Yellowing of the skin getting worse quickly

How is HCC Found?

Screening: If you have cirrhosis or are at high risk (e.g., chronic hepatitis B), your doctor will recommend regular ultrasound scans every 6 months to check for early signs of liver cancer. Finding cancer early greatly improves treatment success.

Diagnosis: If a suspicious area is found, you may have:

• CT or MRI scan: Special scans that can identify HCC based on how it looks after contrast dye is injected.
• Blood tests: A protein called alpha-fetoprotein (AFP) is often elevated in HCC, though not always.
• Biopsy: Taking a small sample of liver tissue (not always needed if scans are typical for HCC).

How is HCC Treated?

Treatment depends on:

1. Size and number of tumours
2. How well your liver is working (since it may already be damaged by cirrhosis)
3. Your overall health

Curative Treatments (Aim to Remove or Destroy the Cancer):

• Surgery to Remove the Tumour (Resection):

  • Suitable if the tumour is small and your liver function is good.
  • Part of the liver is removed; the liver can regrow.

• Liver Transplant:

  • Replaces your diseased liver with a healthy donor liver.
  • Removes both the cancer and the underlying liver disease.
  • Best long-term results, but organ availability is limited.
  • You will need lifelong medications to prevent rejection.

• Ablation (Destroying the Tumour):

  • Uses heat (radiofrequency or microwave energy) to kill cancer cells.
  • Done through the skin with a needle, guided by ultrasound or CT.
  • Good option for small tumours (less than 3cm).

Treatments to Control the Cancer (If Cure is Not Possible):

• TACE (Transarterial Chemoembolisation):

  • A thin tube (catheter) is inserted into an artery in your groin and guided to the liver.
  • Chemotherapy is delivered directly to the tumour, and blood supply is blocked.
  • May need several sessions.

• TARE (Radioembolisation):

  • Tiny radioactive beads are delivered to the tumour through a catheter.
  • Kills cancer cells with targeted radiation.

• Immunotherapy and Targeted Drugs:

  • Medications given as drips or tablets that attack cancer cells or help your immune system fight the cancer.
  • The combination of atezolizumab and bevacizumab is now the main treatment for advanced HCC that cannot be removed.

Supportive Care: If the cancer is very advanced or your liver function is poor, the focus may be on keeping you comfortable and managing symptoms (pain relief, fluid drainage, nutritional support).

Can HCC Be Prevented?

Yes, in many cases:

1. Hepatitis B Vaccination:

   • Highly effective at preventing hepatitis B infection.
   • Given to babies and at-risk adults in most countries.

2. Hepatitis C Treatment:

   • Modern antiviral drugs can cure hepatitis C in 8-12 weeks.
   • Reduces liver cancer risk by 70-80%.

3. Reduce Alcohol Intake:

   • If you have liver disease, stopping alcohol completely can prevent further damage.

4. Maintain a Healthy Weight:

   • Prevents fatty liver disease (NASH/MASH).
   • Eat a balanced diet and exercise regularly.

5. Screening if You're at Risk:

   • If you have cirrhosis or chronic hepatitis B, regular ultrasound scans every 6 months can catch cancer early when it's easier to treat.

What is the Outlook?

The outlook depends on how early the cancer is found:

• Early stage (small tumours, good liver function): Surgery, transplant, or ablation can be curative. 5-year survival is 50-80%.
• Intermediate stage (larger or multiple tumours): Treatments like TACE can control the cancer for months to years.
• Advanced stage (cancer has spread): Median survival is 12-19 months with modern immunotherapy.

Remember: Finding HCC early through screening saves lives. If you have cirrhosis or chronic hepatitis, regular check-ups are essential.

---

12. References

Primary Guidelines

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019

2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 [PMID: 33538338]

3. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1-61. doi:10.1016/bs.acr.2020.10.001 [PMID: 33579421]

4. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521-530. doi:10.1016/S1470-2045(22)00078-X [PMID: 35255263]

5. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84-S101. doi:10.1016/j.jhep.2016.02.021 [PMID: 27084040]

6. Cunha GM, Fowler KJ, Marked off LS, et al. Imaging diagnosis of hepatocellular carcinoma: LI-RADS. Chin Clin Oncol. 2021;10(1):3. doi:10.21037/cco-20-107 [PMID: 32527115]

7. Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816-830. doi:10.1148/radiol.2018181494 [PMID: 30251931]

8. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-338. doi:10.1055/s-2007-1007122 [PMID: 10518312]

9. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905. doi:10.1056/NEJMoa1915745 [PMID: 32402160]

10. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030 [PMID: 34902530]

11. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. doi:10.1002/hep.29913 [PMID: 29624699]

12. Ramai D, Tai W, Rivera M, et al. Utilization of Hepatocellular Carcinoma Surveillance Programs in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2023;57(2):162-173. doi:10.1097/MCG.0000000000001671 [PMID: 34999648]

13. Yilma M, Tulla KA, Robson P, Hernandez-Alejandro R. Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2024;33(1):127-145. doi:10.1016/j.soc.2023.06.008 [PMID: 37945139]

14. Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21(21):8165. doi:10.3390/ijms21218165 [PMID: 33142892]

15. Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel). 2019;11(8):1084. doi:10.3390/cancers11081084 [PMID: 31387280]

16. Magyar CTJ, Harkus U, Paradis V, et al. Precision surgery for hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10(4):366-377. doi:10.1016/S2468-1253(24)00367-3 [PMID: 39993401]

17. Marsh TL, Parikh ND, Mehta N, et al. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis. Gastroenterology. 2025;168(2):349-358.e7. doi:10.1053/j.gastro.2024.09.010 [PMID: 39293548]

18. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73 Suppl 1(Suppl 1):4-13. doi:10.1002/hep.31288 [PMID: 32319693]

19. Nahon P, Bourcier V, Layese R, et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017;152(1):142-156.e2. doi:10.1053/j.gastro.2016.09.009 [PMID: 27641509]

20. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431 [PMID: 26707365]

21. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3 [PMID: 33479224]

22. Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, et al. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42(3):629-652. doi:10.1007/s10555-023-10084-4 [PMID: 36729264]

23. Haber PK, Castet F, Torres-Martin M, et al. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology. 2021;161(3):879-898. doi:10.1053/j.gastro.2021.06.008 [PMID: 34126063]

---

END OF DOCUMENT